Company Profile (AI Text)
Name: Anywhere Dx
Canonical URL: https://wefunder.com/anywhere.dx
Updated at: 2026-06-13T03:05:36Z

Tagline: At-home diagnostics for time-sensitive infections: starting with strep.

Key claims:
- Total raised on Wefunder: 80449 | citation: https://wefunder.com/anywhere.dx#claim-total-raised
- Total investors: 36 | citation: https://wefunder.com/anywhere.dx#claim-total-investors

Verified facts:
- Total raised on Wefunder: 80449 | observed_at: 2026-06-13T03:05:36Z | expires_at: 2026-06-14T03:05:36Z
- Total investors: 36 | observed_at: 2026-06-13T03:05:36Z | expires_at: 2026-06-14T03:05:36Z

Computed metrics:
- total_amount_raised: 80449
- total_investors: 36
- team_size: 4
- featured_investor_count: 3
- faq_count: 2
- recent_post_count: 0

Quick facts:
- Lab-quality accuracy at home ~98% sensitivity / 97% specificity (prototype) | citation: https://wefunder.com/anywhere.dx#claim-fact-1
- From symptom → treatment in under an hour Test, telehealth, and prescription in one flow | citation: https://wefunder.com/anywhere.dx#claim-fact-2
- Built for mass adoption Target price under $25, no clinic required | citation: https://wefunder.com/anywhere.dx#claim-fact-3
- Backed by NSF + NIH Non-dilutive funding validating the technology | citation: https://wefunder.com/anywhere.dx#claim-fact-4
- Not a single test—a platform Expansion roadmap includes UTIs, STIs, Flu/RSV, and more | citation: https://wefunder.com/anywhere.dx#claim-fact-5
- Massive market opportunity Targeting a $64B diagnostics category | citation: https://wefunder.com/anywhere.dx#claim-fact-6
- World-class team Led by Dr. Michael Mina (Harvard/Broad, test-to-treat leader) | citation: https://wefunder.com/anywhere.dx#claim-fact-7
- Early entry before scale inflection Invest ahead of commercialization and Seed round | citation: https://wefunder.com/anywhere.dx#claim-fact-8

FAQ:
- Q: Other than of course raising funds, what's your next operational steps - (a) what are you working on that doesn't require you to raise beyond $1M and (b) what's key item you'll work on upon raising $1M?
  A: James, thank you for asking. I want to make sure I answer this with precision because milestone-based thinking is exactly how we run this company.Our current Wefunder raise targets $300K, serving as a bridge to a $ 5M-priced seed round we are actively building toward. So let me answer in those terms, because that is the honest picture:We are in the final stages of analytical validation for our Strep A assay, while advancing our manufacturing partnership and building our FDA pre-submission. Th...
- Q: Hello, I have some questions. I apologize if these were already answered in the pitch. What specific FDA pathway do you expect for the at-home Strep A test, and what milestones remain before submission and clearance? The pitch deck says q2 2026 for this “de novo vs 510k” How m...
  A: Thank you, Ali, for these questions. This is exactly the kind of diligence we welcome, and I will answer each one directly.On the FDA pathway, we are targeting 510(k) clearance for our at-home Strep A test. The Q2 2026 date in the deck has been updated, and our current near-term milestone is a Q-sub meeting with the FDA, which is the formal pre-submission step that aligns us with the agency on our pathway and data requirements before we proceed to submission.For clinical samples, we are progr...